| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H30N4O3 |
| Molar mass | 410.518 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Protonitazene is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug since 2019, and has been identified in various European countries, as well as Canada, the US and Australia. It has been linked to numerous cases of drug overdose, and is a Schedule I drug in the US.
It was developed by a Swiss pharmaceutical company in the 1950s as an alternative to morphine, but was never adopted due to severe side effects.
Protonitazen er et syntetisk opioid som ble utviklet av et sveitsisk legemiddelselskap på 50-tallet. Det var ment som et alternativ til morfin, men på grunn av alvorlige bivirkninger ble stoffet aldri tatt i bruk.[Protonitazen is a synthetic opioid that was developed by a Swiss pharmaceutical company in the 50s. It was intended as an alternative to morphine, but due to severe side effects, the drug was never used.]